TY - JOUR ID - gesda-tr-2-2-1 UR - https://www.science.org/content/article/cutting-edge-crispr-gene-editing-appears-safe-three-cancer-patients. AU - J. Couzin-Frankel PY - 6 TI - Cutting-Edge CRISPR Gene Editing Appears Safe in Three Cancer Patients T2 - Science ER - TY - JOUR ID - gesda-tr-2-2-2 UR - https://doi.org/10.1186/s12943-023-01738-6. AU - Z. Liu PY - 2023 VL - 22 SP - 35 TI - Recent Advances and Applications of CRISPR-Cas9 in Cancer Immunotherapy T2 - Molecular Cancer ER - TY - JOUR ID - gesda-tr-2-2-3 UR - https://www.npr.org/sections/health-shots/2022/12/13/1140384354/crispr-improves-cancer-immunotherapy-car-t-cell. AU - R. Stein PY - 13 TI - CRISPR Gene-Editing May Boost Cancer Immunotherapy, New Study Finds T2 - NPR ER - TY - JOUR ID - gesda-tr-2-2-4 UR - https://doi.org/10.1038/d41586-020-03476-x. AU - H. Ledford PY - 2020 VL - 588 SP - 383 TI - CRISPR Gene Therapy Shows Promise against Blood Diseases T2 - Nature ER - TY - JOUR ID - gesda-tr-2-2-5 UR - https://doi.org/10.1056/NEJMoa2031054. AU - H. Frangoul PY - 2021 VL - 384 SP - 252 TI - CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia T2 - New England Journal of Medicine ER - TY - JOUR ID - gesda-tr-2-2-6 UR - https://clinicaltrials.gov/ct2/show/NCT03745287. AU - V. Pharmaceuticals PY - 2022 TI - A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease T2 - clinicaltrials.gov ER -